As reported in Xconomy, Allozyne has licensed a technology from Sigma-Aldrich for linking certain compounds to protein drugs. The license covers both therapeutic and diagnostic uses. Allozyne is currently working to modify therapeutic agents to increase circulation time in the blood stream and reduce the number of injections required. This deal follows another protein modification licensing deal Allozyne struck last month with Scripps Research Institute.
Posted by Bruce Lehr August 12th 2010.